{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T13:10:25Z","timestamp":1773061825393,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"48","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T00:00:00Z","timestamp":1476662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.vaccine.2016.10.028","type":"journal-article","created":{"date-parts":[[2016,10,21]],"date-time":"2016-10-21T01:00:15Z","timestamp":1477011615000},"page":"5923-5928","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Immunogenicity of live attenuated Japanese encephalitis SA 14-14-2 vaccine among Sri Lankan children with previous receipt of inactivated JE vaccine"],"prefix":"10.1016","volume":"34","author":[{"given":"Pushpa Ranjan","family":"Wijesinghe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.R. Nihal","family":"Abeysinghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sutee","family":"Yoksan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yafu","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benli","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica A.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony A.","family":"Marfin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Victor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.10.028_b0005","series-title":"Vaccines","first-page":"919","article-title":"Japanese encephalitis","author":"Halstead","year":"2004"},{"key":"10.1016\/j.vaccine.2016.10.028_b0010","first-page":"357","article-title":"Japanese encephalitis: status of surveillance and immunization in Asia and the Western Pacific, 2012","volume":"88","author":"World Health Organization","year":"2013","journal-title":"WHO Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2016.10.028_b0015","unstructured":"World Health Organization. WHO prequalified vaccines. https:\/\/extranet.who.int\/gavi\/PQ_Web\/ [accessed 2016 Sep 30]."},{"key":"10.1016\/j.vaccine.2016.10.028_b0020","unstructured":"World Health Organization. Japanese encephalitis vaccine (live) (5 dose vial); 2016. http:\/\/www.who.int\/immunization_standards\/vaccine_quality\/pq_271_je_5dose_chengdu\/en\/ [accessed 2016 Sep 30]."},{"key":"10.1016\/j.vaccine.2016.10.028_b0025","doi-asserted-by":"crossref","first-page":"285","DOI":"10.4049\/jimmunol.99.2.285","article-title":"A plaque reduction test for dengue virus neutralizing antibodies","volume":"99","author":"Russell","year":"1967","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2016.10.028_b0030","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1016\/j.vaccine.2005.07.002","article-title":"Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2\u20133 September, 2004","volume":"23","author":"Hombach","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.028_b0035","unstructured":"World Health Organization. Annex 7: recommendations to assure the quality, safety, and efficacy of Japanese encephalitis vaccines (live, attenuated) for human use; 2014; Report no.: 980."},{"key":"10.1016\/j.vaccine.2016.10.028_b0040","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/j.vaccine.2008.02.042","article-title":"Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants","volume":"26","author":"Gatchalian","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.028_b0045","series-title":"Immunization handbook, national expanded programme on immunization, Sri Lanka","first-page":"84","author":"Epidemiological Unit Sri Lanka","year":"2002"},{"key":"10.1016\/j.vaccine.2016.10.028_b0050","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/j.ijid.2008.05.132","article-title":"The landscape of new vaccines for Japanese encephalitis: country-level strategies for introduction (abstract)","volume":"12","author":"Abeysinghe","year":"2008","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.10.028_b0055","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.vaccine.2013.12.047","article-title":"A cohort event monitoring to determine the adverse events following administration of mouse brain derived, inactivated Japanese encephalitis vaccine in an endemic district in Sri Lanka","volume":"32","author":"De Alwis","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.028_b0060","first-page":"1","article-title":"Revised guidelines on introduction of live attenuated JE vaccine SA 14-14-2 to the national immunization program","volume":"37","author":"Epidemiological Unit Sri Lanka","year":"2010","journal-title":"Wkly Epidemiol Rep"},{"key":"10.1016\/j.vaccine.2016.10.028_b0065","series-title":"Japanese encephalitis: a manual for medical officers","author":"Epidemiological Unit Sri Lanka","year":"2011"},{"key":"10.1016\/j.vaccine.2016.10.028_b0070","unstructured":"Fourth bi-regional meeting of the control of Japanese encephalitis a: report of the meeting. Bangkok (Thailand) and New Delhi: SEARO; 2010."},{"key":"10.1016\/j.vaccine.2016.10.028_b0075","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0264-410X(96)00170-3","article-title":"Systemic immediate-type reactions to gelatin included in Japanese encephalitis vaccines","volume":"15","author":"Sakaguchi","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.028_b0080","first-page":"331","article-title":"Japanese encephalitis vaccines","volume":"81","author":"World Health Organization","year":"2006","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2016.10.028_b0085","unstructured":"Program for Appropriate Technology in Health (PATH). PATH\u2019s Japanese encephalitis project: collaboration and commitment to protect Asia\u2019s children. PATH; 2009."},{"key":"10.1016\/j.vaccine.2016.10.028_b0090","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1016\/S0264-410X(99)00006-7","article-title":"Primary and booster immune responses to SA14-14-2 Japanese encephalitis vaccine in Korean infants","volume":"17","author":"Sohn","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.028_b0095","first-page":"1","article-title":"Inactivated Japanese encephalitis virus vaccine. recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"42","author":"Centers for Disease Control and Prevention","year":"1993","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2016.10.028_b0100","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/infdis\/161.5.878","article-title":"Evaluation of the potency and safety of inactivated Japanese encephalitis vaccine in US inhabitants","volume":"161","author":"Poland","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.10.028_b0105","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1086\/517323","article-title":"Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2): results of a randomized trial with 26,239 subjects","volume":"176","author":"Liu","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.10.028_b0110","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1016\/j.vaccine.2007.04.052","article-title":"Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5years after immunization","volume":"25","author":"Tandan","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.10.028_b0115","first-page":"37","article-title":"Global Advisory Committee on Vaccine Safety, 12\u201313 December 2007","volume":"83","author":"World Health Organization","year":"2008","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2016.10.028_b0120","unstructured":"World Health Organization. Guidelines for plaque reduction neutralization testing of human antibodies to dengue viruses; 2007."},{"key":"10.1016\/j.vaccine.2016.10.028_b0125","series-title":"Introduction of live attenuated JE vaccine SA14-14-2 (LJEV) to the national immunization programme","author":"Epidemiological Unit Sri Lanka","year":"2009"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1630946X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1630946X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T02:55:26Z","timestamp":1718852126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1630946X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":25,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S0264410X1630946X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.10.028","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity of live attenuated Japanese encephalitis SA 14-14-2 vaccine among Sri Lankan children with previous receipt of inactivated JE vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.10.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}